Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years
First written in FY2021. 7 of 16 entries say "Advanced", first in FY2022-Q2. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In the fiscal year ending June 2025, the Healthcare Solutions Business, as it was then known, achieved segment profitability and was placed on a stable growth trajectory.」
For the former Healthcare Solutions Business, the company explicitly stated that segment profit turned positive in the fiscal year ending June 2025. Revenue from the functional material development support service also reached ¥363.885 million in the fiscal year ending June 2026. - 2026-08-20AdvancedFinancial results briefing materials
「• Revenue from the functional materials development support service expanded to just under ¥400 million in the final year • Achieved profitability from the fiscal year ending June 2025」
The functional materials development support service expanded to revenue of just under ¥400 million and became profitable from the fiscal year ending June 2025, although this was distinct from achieving the overall previous revenue target. - FY2025-H1AdvancedAnnual report
「As a result, revenue was ¥156.680 million, up 35.2% year on year. The shift in research and development investment to the Advanced Research and Development Support Business substantially reduced segment expenses, resulting in segment profit after the allocation of company-wide expenses of ¥28.550 million, compared with a segment loss of ¥23.025 million in the same period of the previous year.」
Revenue in the Healthcare Solutions Business increased 35.2% year on year, and the business turned from a segment loss to profit of ¥28.550 million. This demonstrated concrete earnings progress toward the 5-year revenue growth and profitability targets. - FY2024AdvancedAnnual report
「Revenue increased substantially following the expansion of sales of the comprehensive support service for functional material development and the receipt of a large paid joint development project related to functional materials, among other factors.」
Revenue in the Healthcare Solutions Business increased 234.4%, from ¥47.487 million to ¥158.818 million, while the segment loss narrowed from ¥142.627 million to ¥90.532 million. - FY2024-Q3AdvancedAnnual report
「In this business segment, revenue increased substantially following the receipt of a large paid joint development project related to functional materials, among other factors. Revenue from skin-gas measurements and other services also remained firm. In research and development, we pursued additional development of the comprehensive support service for functional material development and other offerings. As a result, revenue was ¥152.192 million, up 415.6% year on year, and the segment loss after the allocation of company-wide expenses was ¥47.446 million, compared with a segment loss of ¥110.321 million in the same period of the previous year.」
Revenue increased 415.6% year on year following the receipt of a large paid joint development project, while the segment loss narrowed from the same period of the previous year. - FY2024-Q2AdvancedAnnual report
「In this business segment, revenue increased substantially following the receipt of a large paid joint development project related to functional materials. Revenue from skin-gas measurements and other services also remained firm. In research and development, we pursued additional development of the comprehensive support service for functional material development and other offerings, as well as joint development of mental health biomarkers. As a result, revenue was ¥115.910 million, up 410.2% year on year, and the segment loss after the allocation of company-wide expenses was ¥23.025 million, compared with a segment loss of ¥69.357 million in the same period of the previous year.」
Revenue increased 410.2% year on year following the receipt of a large paid joint development project, while the segment loss narrowed from ¥69.357 million to ¥23.025 million. - FY2024-Q1MitigatedAnnual report
「In this business segment, we worked to expand orders for and pursue additional development of the comprehensive support service for functional material development and other offerings, while promoting business partnerships for new services and joint development of mental health biomarkers. As a result, revenue was ¥13.983 million, up 105.4% year on year, and the segment loss after the allocation of company-wide expenses was ¥34.629 million, compared with a segment loss of ¥37.251 million in the same period of the previous year.」
The Healthcare Solutions Business expanded orders and pursued additional development, among other initiatives, resulting in higher revenue and a smaller segment loss than in the same period of the previous year. - FY2023RaisedAnnual report
「As development investment is front-loaded in this business segment, losses are expected to continue for the time being. However, through continued cost-effective development investment, we aim for revenue of ¥250 million in the fiscal year ending June 2026 and seek to record segment profit before company-wide common allocated expenses.」
The revenue target was raised from the previous target of approximately ¥100 million in 5 years to ¥250 million for the fiscal year ending June 2026. Meanwhile, the segment loss in FY2023 was ¥142.627 million. - FY2023-Q3WorsenedAnnual report
「In this business segment, we expanded orders for and pursued additional development of the comprehensive support service for functional material development and other offerings, while promoting business partnerships for new services and joint development of mental health biomarkers. We also promoted research and development for new businesses targeting healthcare-related companies, resulting in higher research and development expenses. As a result, revenue was ¥29.520 million, up 990.8% year on year, and the segment loss after the allocation of company-wide expenses was ¥110.321 million, compared with a segment loss of ¥89.714 million in the same period of the previous year.」
While expanding sales of new services and advancing research and development, revenue increased to ¥29.520 million, but the segment loss expanded to ¥110.321 million. Near-term earnings performance has deteriorated against the 5-year revenue and profitability targets. - FY2023-Q2WorsenedAnnual report
「As a result, revenue was ¥22.716 million, up 881.5% year on year, and the segment loss after allocation of company-wide expenses was ¥69.357 million, compared with a segment loss of ¥56.258 million in the same period of the previous year.」
Against the 5-year revenue and segment profitability targets, revenue increased, while the segment loss expanded from the same period of the previous year. - FY2023-Q1WorsenedAnnual report
「As a result, revenue was ¥6.809 million, compared with revenue of ¥0.004 million in the same period of the previous year, and the segment loss after allocation of company-wide expenses was ¥37.251 million, compared with a segment loss of ¥24.914 million in the same period of the previous year.」
Against the 5-year revenue and segment profitability targets, revenue increased to ¥6.809 million in the current quarter, while the segment loss expanded to ¥37.251 million. - FY2022WorsenedAnnual report
「As a result of continuing contract research testing and other activities, revenue was ¥2.856 million, down 36.2% year on year. The segment loss was ¥140.842 million, compared with a segment loss of ¥101.980 million in the same period of the previous year, reflecting increased R&D investment.」
While Metabolome Index and the skin-gas measurement service were launched, the Healthcare Solutions Business reported lower revenue, and its loss expanded due to increased research and development investment. - FY2022-Q3WorsenedAnnual report
「As a result, revenue was ¥2.706 million, up 9.5% year on year, and the segment loss was ¥89.714 million, compared with a segment loss of ¥80.036 million in the same period of the previous year.」
While revenue increased, the Healthcare Solutions Business’s segment loss expanded from the same period of the previous year. - FY2022-Q2AdvancedAnnual report
「We launched Metabolome Index in December as a biomarker discovery service and will work to expand sales of the service going forward.」
The new service in the Healthcare Solutions Business was launched, and the business moved into the phase of expanding sales. - FY2022-Q1RestatedAnnual report
「In this business segment, we efficiently continued the joint development of PEA (a depression biomarker) and the expansion of contract research testing services, among other initiatives. We also continued to work on development toward the launch of a biomarker discovery service and the promotion of joint development for healthcare solutions services.」
PEA, exploratory services, and joint development are continuing toward the Healthcare Solutions Business’s 5-year revenue and segment profitability targets. - FY2021First statedAnnual report
「The segment is expected to continue reporting losses for the time being, but through continued cost-effective development investment, we aim to generate approximately ¥100 million in revenue in 5 years and record segment profit before company-wide common allocated expenses.」
For the Healthcare Solutions Business, the company for the first time stated a target of generating approximately ¥100 million in revenue in 5 years and recording segment profit before company-wide common allocated expenses, using cost-effective development investment as the means to achieve it.